Illia Leibering
Primary Care · Tell City, INNPI 1275201113
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,423 and has fallen 90.9% since, to $129 in 2025. Among primary care clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$378
- AbbVie$303
- Merck$255
- Amgen$241
- Novo Nordisk$230
- AstraZeneca$229
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,087100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $378 |
| AbbVie | 24 | $303 |
| Merck | 14 | $255 |
| Amgen(2 entities) | 13 | $241 |
| Novo Nordisk | 13 | $230 |
| AstraZeneca | 13 | $229 |
| Pfizer | 13 | $190 |
| Novartis | 9 | $137 |
| Sumitomo Pharma America, Inc. | 7 | $103 |
| Axsome Therapeutics, Inc. | 6 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $88 |
| Organogenesis Inc. | 1 | $78 |
| Lundbeck LLC | 4 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Johnson & Johnson | 4 | $65 |
| Mylan Specialty L.p. | 3 | $65 |
| Bayer | 4 | $58 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Lilly USA, LLC | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Corcept Therapeutics | 1 | $16 |
| Corium, LLC | 1 | $4 |
How this compares
$3,087 in reported general payments places this provider in the 90th percentile of 113 primary care providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 15 | $16,444 |
| FarxigaDapagliflozin Propanediol | 24 | $15,633 |
| SynthroidLevothyroxine Sodium | 12 | $1,017 |
| Azelastine Hcl | 22 | $830 |
| Carbamazepine ErCarbamazepine | 12 | $697 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $481 |
| Sertraline Hcl | 19 | $212 |
| Atorvastatin Calcium | 35 | $200 |
| Testosterone Cypionate | 13 | $195 |
| Escitalopram Oxalate | 12 | $191 |
| Methylprednisolone | 23 | $177 |
| Levothyroxine Sodium | 29 | $131 |
| Terazosin Hcl | 11 | $125 |
| Metformin Hcl | 31 | $123 |
| Losartan Potassium | 12 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $230 | $16,44415 claims |
| AstraZenecaFarxiga | $229 | $15,63324 claims |
| AbbVieSynthroid | $303 | $1,01712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 113 primary care providers in Indiana.
Other primary care in Tell City
- Katrina MotleyIndianapolis$18K
- Stephanie BodamerBloomington$6K
- Candace KapranosGary$5K
- Jalyn GoolsbyNew Albany$4K
- Ashley VirtMuncie$4K
- Lana HumeCarmel$3K
- Jiyoung ChaeWest Lafayette$3K
- Leigha Bowyer-JonesJeffersonville$3K
- Heather PickettNoblesville$2K
- Abigail BurkeSheridan$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.